Estimating average glucose levels from glycated albumin in patients with end-stage renal disease by 諛뺤젙�긽 et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 3   May 2012578
Original Article http://dx.doi.org/10.3349/ymj.2012.53.3.578pISSN: 0513-5796, eISSN: 1976-2437          Yonsei Med J 53(3):578-586, 2012
Estimating Average Glucose Levels from Glycated Albumin  
in Patients with End-Stage Renal Disease
Jwa-Kyung Kim, Jung Tak Park, Hyung Jung Oh, Dong Eun Yoo, Seung Jun Kim,  
Seung Hyeok Han, Shin-Wook Kang, Kyu Hun Choi, and Tae-Hyun Yoo
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. 
Received: May 27, 2011
Revised: August 31, 2011
Accepted: September 8, 2011
Corresponding author: Dr. Tae-Hyun Yoo,
Department of Internal Medicine, 
Yonsei University College of Medicine,
50 Yonsei-ro, Seodaemun-gu,
Seoul 120-752, Korea. 
Tel: 82-2-2228-1989, Fax: 82-2-393-6884  
E-mail: yoosy0316@yuhs.ac
· Parts of this work were presented in an 
abstract at the annual meeting of the American 
Society of Nephrology; November 16 through 
21, 2010 in Denver, CO, USA.
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2012
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: In patients with diabetic end stage renal disease (ESRD), glycated albu-
min (GA) reflects recent glycemic control more accurately than glycated hemoglo-
bin (HbA1c). We evaluated the relationship between GA and average blood glucose 
(AG) level and developed an estimating equation for translating GA values into 
easier-to-understand AG levels. Materials and Methods: A total of 185 ESRD 
patients, including 154 diabetic and 31 non-diabetic participants, were enrolled 
(108 hemodialysis, 77 peritoneal dialysis). Patients were asked to perform four-
point daily self-monitoring of capillary blood glucose (SMBG) at least three con-
secutive days each week for four weeks. Serum levels of GA, HbA1c and other 
biochemical parameters were checked at baseline, as well as at 4 and 8 weeks. Re-
sults: Approximately 74.3±7.0 SMBG readings were obtained from each partici-
pant and mean AG was 169.1±48.2 mg/dL. The correlation coefficient between se-
rum GA and AG levels (r=0.70, p<0.001) was higher than that of HbA1c and AG 
(r=0.54, p<0.001). Linear regression analysis yielded the following equation: esti-
mated AG (eAG) (mg/dL)=4.71×GA%+73.35, and with this formula, serum GA 
levels could be easily translated to eAG levels. Multivariate analysis revealed sig-
nificant contributions of postprandial hyperglycemia (β=0.25, p=0.03) and serum 
albumin (β=0.17, p=0.04) in determining serum GA level, independent to other 
clinical parameters. Conclusion: Compared to HbA1c, serum GA levels were bet-
ter correlated with AG levels. Using the estimating equation, an average blood glu-
cose level of 155-160 mg/dL could be matched to a GA value of 18-19% in pa-
tients with ESRD.
Key Words:  Average blood glucose, end-stage renal disease, glycated albumin, 
self-monitoring blood glucose
INTRODUCTION
Numerous studies have emphasized the importance of strict blood glucose control 
for protecting against microvascular and macrovascular diabetic complications.1-4 
In addition to patients without overt diabetic nephropathy, the benefits of adequate 
glycemic control have also been emphasized in patients with end-stage renal dis-
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derstand AG levels in ESRD patients, including peritoneal 
dialysis (PD) patients. 
Therefore, we sought to confirm the measurement of GA 
as a substitute to HbA1c quantification for the accurate as-
sessment of glycemic control in patients with ESRD. More-
over, we attempted to develop an estimating equation for 
investigating the relationship between GA and AG levels. 
The optimal target range for GA in diabetic dialysis patients 
was also examined in this study.
MATERIALS AND METHODS
　　　
Study sample
This was a single-center prospective study conducted at 
Severance Hospital in Korea between March 2010 and Oc-
tober 2010. Type 1 and 2 diabetic ESRD patients as well as 
non-diabetic patients between the ages of 18 and 70 years 
were recruited. Diabetic patients received either an oral hy-
poglycemic agent, insulin or both, and were required to 
have relatively stable glycemic control as manifested by at 
least two HbA1c results in the previous six months with no 
more than 1% difference. Patients were also classified as 
hemodialysis (HD) or PD group according to modality of 
maintaining dialysis during the study period. The duration 
of diabetes was determined based on medical records. For 
patients not diagnosed at our center, however, the duration 
was presumed based on the patients’ medical history. Non-
diabetic patients included those with no history of diabetes, 
a plasma glucose level <126 mg/dL after an overnight fast, 
and an HbA1c level <6.5% at the time of presentation. Cri-
teria for exclusion were extremely young or old age, pres-
ence of severe diabetic retinopathy, history of recent hospi-
talization, and non-compliance. Patients with complicated 
comorbid conditions or who had taken medications that 
could influence plasma glucose levels during the previous 
three-month period were also excluded. This study was per-
formed with approval from the local Institutional Review 
Board, and informed consent was obtained from all partici-
pants.
Glucose measurements
To measure casual blood glucose level, all participants were 
asked to perform four-point daily self-monitoring of capil-
lary blood glucose (SMBG) (OneTouch Ultra; Lifescan, 
Milipitas, CA, USA) for at least three consecutive days per 
week for four weeks. Capillary blood glucose was typically 
ease (ESRD), even after the start of dialysis.2-5 A seven-year 
observational study with 114 diabetic hemodialysis patients 
showed significantly higher mortality and worse prognoses 
in patients with poor glycemic control (HbA1c ≥8.0%).6 
Shima, et al.7 also reported that intensive management of 
diabetic control at a stringent mean postprandial glucose 
level of less than 180 mg/dL could improve the life expec-
tancy of diabetic dialysis patients. Although an issue of 
considerable debate, currently recommended glucose tar-
gets in ESRD patients are identical to those for the general 
population:8 a fasting blood glucose level below 140 mg/
dL, a postprandial value of less than 200 mg/dL, and HbA1c 
less than 6.5-7%.9-11
To date, HbA1c has been the most widely recognized 
marker of glycemic control, reflecting one’s average glyce-
mic status for the preceding 2 to 3 months.12 However in 
ESRD patients, the availability of HbA1c is a limitation to its 
use as a marker of glycemic control, because it can be influ-
enced by various clinical factors such as reduced red-blood 
cell (RBC) lifespan, recent transfusion, iron deficiency, met-
abolic acidosis or frequent erythropoietin injection.10-13 As a 
result, HbA1c tends to underestimate glycemic status, espe-
cially in patients with reduced renal function.12,14,15 On the 
basis of a study involving Japanese hemodialysis patients, 
serum glycated albumin (GA) has been proposed as an alter-
native marker of glycemic control in dialysis patients,12 
since levels of GA are unaffected by changes in RBC sur-
vival time or erythropoietin use.16 Compared to HbA1c, GA 
responds much sooner to changes in glycemic levels, re-
flecting short-term glycemic control over the previous 2 to 3 
weeks. Furthermore, serum GA may also be a marker of the 
development of cardiovascular diseases.17 In an observation-
al study by Fukuoka, et al.,5 high GA (≥29%) was a signifi-
cant predictor of cardiovascular death compared to low GA 
(<29%), but this was not observed with HbA1c. Similarly, 
Yamada, et al.18 showed that serum GA level, not HbA1c, is 
closely associated with peripheral vascular calcification and 
pulse-wave velocity, an indicator of advanced atherosclero-
sis and arterial stiffness in diabetic dialysis patients.
Nevertheless, there are some limitations to the use of GA 
in clinical practice, due to lack of validated reference rang-
es; even though the GA/HbA1c ratio is usually estimated as 
3.0, this empirical estimate has no statistical background.19 
Furthermore compared to HbA1c, for which there is an es-
tablished equation to translate it into average glucose (AG) 
values,20-22 there have been few reports on the mathematical 
method of converting GA measurements into easier-to-un-
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standard deviation (SD) or as percentages. Chi-square and 
independent t-tests were used to compare the DM with 
non-DM group or HD with PD group. Pearson’s correlation 
coefficients were calculated to assess the strengths of the 
relationships between clinical variables. Simple linear re-
gression was used to determine the association between av-
erage glucose level and GA or HbA1c, and to create a mathe-
matical equation. For regression analysis, GA at 4 weeks 
and HbA1c at 8 weeks were used in consideration of their 
reflectiveness on glucose levels for their respective periods. 
Analyses of the significant contributing factors for GA 
were performed using multiple regression analysis. Statisti-
cal Package for the Social Sciences (SPSS) for Windows 
Ver. 15.0 (SPSS Inc., Chicago, IL, USA) was used and p-
values <0.05 were considered statistically significant. 
 
RESULTS
 
Baseline characteristics
A total of 185 ESRD patients were included in this study. 
Baseline demographic characteristics of the participants are 
summarized in Table 1. Two patients had type 1 diabetes 
mellitus (DM), 152 were type 2 diabetes mellitus and the 
other 31 were non-diabetic ESRD patients. The median du-
ration of diabetes was 204 (10-600) months. The mean age 
was 60.3±13.3 years and patients in the DM group were 
significantly older than those in the non-diabetic group 
(p<0.001). Patients in the DM group had a higher incidence 
of cardiovascular comorbidities (p=0.03), but there were no 
differences in body mass index (BMI), dialysis duration, 
type of dialysis, and baseline laboratory data between the 
DM group and the non-diabetic group, except for serum 
glucose level. In total, 108 (58.3%) patients were on main-
tenance HD, and 77 patients were undergoing PD. The me-
dian durations of HD and PD were 17.0 (9.0-147.0) and 
15.0 (9.0-130.0) months, respectively, and the difference 
was statistically insignificant (p=0.13). When examining 
the baseline characteristics between HD and PD groups, 
AG level was similar (166.3±48.6, 172.9±47.7 mg/dL, 
p=0.350). HD patients were older than those with PD 
(62.9±12.9 years vs. 56.6±13.1 years, p=0.001) and showed 
higher serum albumin levels (3.50±0.6 mg/dL vs. 3.21±0.5 
mg/dL, p<0.001), compared to PD patients. However, there 
was no significant relationship between serum albumin and 
PD duration (r=-0.162, p=0.160) or residual renal function 
(r=0.086, p=0.785) (data not shown). 
tested at fasting (before breakfast), postprandial (120 min 
after breakfast), postabsorptive (at 5:00 P.M), and at bed-
time. To be enrolled in this study, the number of recorded 
SMBGs must have totaled at least 40 measurements or 
more during the study period (a minimum of twice a day 
for at least two days per week). 
A small drop of blood obtained by pricking the skin with 
a lancet was used to measure capillary glucose level, where-
as, serum glucose level was determined using a centrifuged 
blood sample (i.e., serum). While RBCs in whole blood 
have a higher concentration of protein, serum has higher 
water content and consequently more dissolved glucose 
than whole blood. In general, serum glucose level could 
reach a level equal to capillary blood glucose level multi-
plied by 1.15. The results of SMBG tests were recorded 
and any events including overeating, missing a meal, feel-
ings of dizziness, or other symptoms suggesting episodes of 
hypoglycemia were also documented. To encourage blood 
sugar testing and to reduce hypoglycemic events, all pa-
tients were provided appropriate feedback by dialysis staff 
once per week. After eight weeks of initial SMBG, all pa-
tients were asked to measure follow-up SMBG for two 
weeks to verify stable glycemic state.
Average glucose levels for each testing (fasting, post-
prandial, postabsorptive, and bedtime) and the mean glu-
cose value of total SMBG tests were calculated by the area-
under-the-curve (AUC) of each glucose profile using the 
trapezoidal rule.23 
Assays of GA and HbA1c 
Blood samples for serum GA, HbA1c levels and biochemi-
cal parameters including serum hemoglobin, albumin, 
blood urea nitrogen, and creatinine were obtained at base-
line and at the end of 4 and 8 weeks. To confirm the accura-
cy of SMBG results, fasting plasma glucose were measured 
weekly at the dialysis center before the start of each session 
of dialysis and compared with the results of SMBG. 
Serum HbA1c levels were analyzed using routine high-
performance liquid chromatography (HPLC, Bio-Rad Lab-
oratories Inc., Hercules, CA, USA), and GA level was mea-
sured by enzymatic methods using the Lucica GA-L kit 
(Asahi Kasei Pharma Corp., Tokyo, Japan) with an auto-
matic spectrophotometer. GA level was given as a percent-
age of GA divided by the total amount of serum albumin. 
 
Statistical analyses
Demographic biochemical data were expressed as mean± 
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en at 8 weeks, the calculated AUC was 164.3±44.1 mg/dL, 
176.8±37.1 mg/dL, and 100.1±10.9 mg/dL, respectively. 
Correlation coefficients between the two measurements 
were r=0.868 (p<0.001), r=0.800 (p<0.001) and r=0.512 
(p=0.01), respectively. Based on these data, the glycemic 
status of the recruited patients was able to be regarded as 
stable throughout the study period. 
As expected, capillary and plasma glucose levels as well 
Glucose measurements
SMBG by capillary finger stick tests were performed ap-
proximately 74.3±7.0 times per each participant (50.5±13.0 
times during the initial measurement and 22.5±4.5 times 
during follow-up). The mean AG calculated by AUC was 
169.1±48.2 mg/dL for all subjects, 181.6±42.6 mg/dL for di-
abetic patients and 106.8±13.9 mg/dL for non-diabetic pa-
tients (Table 2). For the follow-up glucose measurement tak-
Table 1. Baseline Characteristics of the Patients
All DM Non-DM p value
n (%) 185 154 (83.2) 31 (16.8)
Age (yrs)   60.3±13.3   62.5±11.1   49.3±17.3 <0.001
Gender (n, % male) 111 (60)   91 (59.1) 20 (64.5) 0.57
BMI (kg/m2) 23.5±3.3 23.3±2.6 24.5±5.4 0.22
Smoking (n, %)    118 (63.7) 101 (65.6) 17 (54.8) 0.27
Type of dialysis (%) 0.22
    Hemodialysis    108 (58.4)   93 (60.3) 15 (48.4)
    Peritoneal dialysis      77 (41.6)   61 (39.7) 16 (51.6)
Dialysis vintage (months)*        16 (9-147)        16 (10-130)   16 (9-147) 0.09
Laboratory data
    Hemoglobin (g/dL)   9.8±1.6 10.0±1.6   9.1±1.5 0.17
    Albumin (g/dL)                            3.5±0.6   3.5±0.6   3.6±0.7 0.35
    Urea nitrogen (mg/dL)                            46.2±17.8   46.0±17.6   47.0±19.2 0.77
    Creatinine (mg/dL)   7.2±2.9   7.1±2.7   7.4±3.3 0.23
    Glucose (mg/dL, random) 137.1±39.3 145.1±38.3 99.3±9.8 <0.001
    Total cholesterol (mg/dL)  151.6±43.1 151.6±43.6 151.9±41.3 0.9
History of cardiovascular disease (n, %)       91 (49.2)   81 (52.5) 10 (32.2)  0.03
Management of DM (%) - - -
    OHA (s)   66 (42.8) - -
    Insulin only   54 (35.1) - -
    Insulin+OHA (s)   34 (22.1) - -
DM, diabetes mellitus; BMI, body mass index; OHA, oral hypoglycemic agents; SD, standard deviation.
Others are expressed as mean±SD. 
*Median with ranges. 
Table 2. Glucose Parameters during the Study Period
AUC All (n=185) DM (n=154) Non-DM (n=31) p value
Capillary blood glucose (mg/dL) <0.001
    Fasting (before breakfast) 122.7±36.4 127.5±36.4 90.7±9.8
    Postprandial (120 min after breakfast) 176.6±52.6 186.5±48.2 106.1±16.1
    Postabsorptive (5:00 P.M) 180.8±54.3 187.6±52.5 117.7±19.0
    Before bedtime 206.5±62.8  215.1±58.7 116.0±19.5
    Average 169.1±48.2 181.6±42.6 106.8±13.9
Fasting plasma glucose (mg/dL) 136.8±38.2 148.5±36.4   90.5±11.6 <0.001
Glycated albumin (%) at 4 wks 19.8±7.0 21.4±6.5 10.9±2.3 <0.001
Glycated albumin (%) at 8 wks 19.5±6.6 21.1±6.1 10.7±1.4 <0.001
HbA1c (%) at 4 wks   6.8±1.4   7.2±1.1   6.0±0.9 <0.001
HbA1c (%) at 8 wks   6.8±1.3   7.1±1.3   5.8±0.4   0.010
GA/HbA1c at 4 wks   2.8±0.8   3.1±0.8   1.9±0.4 <0.001
GA/HbA1c at 8 wks   2.9±0.9   3.0±0.8   1.9±0.3 <0.001
DM, diabetes mellitus; GA, glycated albumin; HbA1c, hemoglobin A1c; AUC, area-under-the-curve. 
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two groups. There were no significant intra-individual varia-
tions of GA or HbA1c during the study period.
Correlation between AG and GA or HbA1c 
HbA1c and GA levels were proportional to measured AG. 
The strength of correlation between serum GA and AG lev-
els (r=0.70, p<0.001) was higher than that of HbA1c and 
AG (r=0.54, p<0.001) (Fig. 1). The correlation had a SD of 
prediction error of 7.68 mg/dL for GA and 15.83 mg/dL for 
HbA1c. 
Simple linear regression models revealed a close rela-
tionship between GA and AG levels and yielded an estimat-
ing equation as follows: Mean estimated AG (eAG) (mg/
dL)=4.7×GA%+73.35, R2=0.48. 
As shown in Fig. 1, the scatter around the regression line 
was less wide and the slope of the line was significantly 
steeper between GA and average blood glucose in compari-
son to those of HbA1c, which supported the hypothesis that 
HbA1c levels underestimate mean blood glucose levels. 
Based on the above estimating equation, serum GA values 
were transformed into their equivalent mean eAG (Table 3). 
On average, each change of 10 mg/dL in AG level gave rise 
to 2% changes in GA values. An average blood glucose lev-
el of 155-160 mg/dL, which is equivalent to 7% of HbA1c in 
patients without nephropathy according to the formula of 
Nathan, et al.,20 was matched to a GA value of 18-19% in 
patients with ESRD. 
 
Relationships between clinical parameters and GA, 
HbA1c or GA/HbA1c in diabetic ESRD patients
The results of the correlation analyses between various 
clinical parameters and HbA1c, GA or GA/HbA1c ratio are 
as GA or HbA1c were significantly higher in diabetic pa-
tients: serum GA and HbA1c were 21.4±6.5% and 7.2±1.1% 
at 4 weeks and 21.1±6.1% and 7.1±1.3% at 8 weeks, re-
spectively. Whereas, the level of GA and HbA1c in non-dia-
betic patients was 10.9±2.3% and 6.0±0.9% at 4 weeks and 
10.7±1.4% and 5.8±0.4% at 8 weeks. The mean GA/HbA1c 
ratio (mean values of GA at 4 weeks and HbA1c at 8 weeks) 
was 3.1±0.8 in the DM group and 1.9±0.4 in the non-DM 
group; all of these differences were statistically significant. 
Moreover, there was a significant discrepancy in GA level 
dependent upon dialysis modalities. The mean GA level was 
20.8±7.3% in HD patients and 17.7±5.9% in PD patients 
(p<0.001), probably reflecting the lower level of serum al-
bumin in patients undergoing PD. However, no statistically 
significant difference was observed in HbA1c between these 
Table 3. Estimated Average Glucose from Serum GA Levels 
according to the Regression Equation* 
GA (%)
Estimated blood glucose level by regression analysis
mg/dL mmol/L
12 129.9 (114.6-145.0) 7.2 (6.4-8.1)
13 134.6 (119.3-149.7) 7.5 (6.6-8.3)
14 139.3 (124.0-154.4) 7.7 (6.9-8.6)
15 144.0 (128.8-159.2) 8.0 (7.2-8.8)
16 148.7 (133.5-163.9) 8.3 (7.4-9.1)
17 153.4 (138.2-168.6) 8.5 (7.7-9.4)
18 158.1 (142.9-173.3) 8.8 (7.9-9.6)
19 162.8 (147.6-178.0) 9.0 (8.2-9.9)
20 167.6 (152.3-182.7)   9.3 (8.5-10.2)
21 172.3 (157.0-187.4)   9.6 (8.7-10.4)
22 177.0 (161.7-192.1)   9.8 (9.0-10.7)
GA, glycated albumin.
Data in parentheses are 95% CIs. 
*eAG (mg/dL)=4.71×GA%+73.35, R2=0.48.
Fig. 1. Correlation between AG and serum GA or HbA1c levels. The strength of correlation between serum GA and AG levels (r=0.70, p<0.001, left) was higher 
than that of HbA1c and AG (r=0.54, p<0.001, right). GA, glycated albumin; AG, average blood glucose.
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regression models with diabetic ESRD patients (Table 5). 
In unadjusted analysis (Model 1), fasting and postprandial 
glucose levels as well as serum albumin levels and dialysis 
modality were significant predictors in determining serum 
GA level. Even after adjustment for the clinical and labora-
tory parameters that might influence serum GA level (Mode 
4), a significant positive association of postprandial hyper-
glycemia (β=0.25, p=0.03) and serum albumin (β=0.17, 
p=0.04) with GA level was consistently observed, indepen-
dent of age, BMI, serum hemoglobin, fasting glucose, dura-
tion or type of dialysis.
DISCUSSION
Our data convincingly demonstrated that the measurement 
of GA is a more accurate method of judging glycemic con-
trol in ESRD patients. Similar to previous reports, higher 
shown in Table 4. Serum GA level was closely associated 
with the duration of diabetes (r=0.148, p=0.04) and serum 
albumin (r=0.260, p=0.01), whereas HbA1c level showed a 
significant association with only serum hemoglobin 
(r=0.359, p<0.001). Among the individual time points, 
some different findings were observed: serum GA level 
showed higher correlation with postprandial glucose level 
compared to fasting glucose level (r=0.356, p<0.001 vs. 
r=0.294, p=0.01). However, serum HbA1c showed the op-
posite results, which had a higher correlation with fasting 
glucose level compared to postprandial glucose level 
(r=0.274, p<0.001 vs. r=0.266, p<0.001). In addition, we 
also found a strong and significant correlation with bedtime 
glucose level and GA (r=0.43, p<0.001), suggesting the 
possible role of bedtime glucose level for determining se-
rum GA level. 
To analyze the independent contribution of clinical fac-
tors on serum GA, we constructed a series of multivariate 
Table 4. Correlations between Clinical Parameters and GA, HbA1c or GA/HbA1c Ratio in Diabetic ESRD Patients
Pearson’s correlation coefficient
GA HbA1c GA/HbA1c
Age -0.030 -0.098    0.236*
BMI -0.032  0.128 -0.182
Duration of dialysis  0.348  0.150  0.053
Duration of diabetes    0.148*  0.150  0.071
Fasting blood glucose    0.294*   0.274†  0.082
Postprandial glucose   0.356†   0.266†    0.218*
Hemoglobin  0.160   0.359†  0.057
Albumin   0.260†  0.008    0.236*
Creatinine  0.139  0.069 -0.090
Total cholesterol -0.022  0.074 -0.085
GA, glycated albumin; HbA1c, hemoglobin A1c; BMI, body mass index; ESRD, end stage renal disease.
*p<0.05. 
†p<0.001.
Table 5. Multiple Regression Models of GA in Diabetic ESRD Patients
Model 1 (β, p value)
Model 2 (β, p value) 
(R2=0.39)
Model 3 (β, p value) 
(R2=0.43)
Model 4 (β, p value) 
(R2=0.54)
FBG (mg/dL)    0.29 (0.006) 0.20 (0.12)  0.22 (0.09)  0.18 (0.10)
PPG (mg/dL)    0.36 (0.001) 0.28 (0.01)  0.32 (0.01)  0.25 (0.03)
Hemoglobin (g/dL)  0.16 (0.34) -0.04 (0.62) -0.05 (0.65)
Albumin (g/dL)  0.26 (0.01)  0.33 (0.01)  0.17 (0.04)
Age (yrs) -0.03 (0.71)  0.05 (0.52)
BMI (kg/m2) -0.03 (0.70) -0.10 (0.14)
Duration of dialysis (months)  0.35 (0.14)  0.05 (0.39)
Type of dialysis    0.20 (0.018)  0.14 (0.12)
GA, glycated albumin; FBG, fasting blood glucose; PPG, postprandial glucose; BMI, body mass index; ESRD, end stage renal disease.
Model 1: unadjusted; Model 2: adjusted for fasting and postprandial glucose level; Model 3: model 2+adjusted for serum hemoglobin and albumin levels; 
Model 4: model 3+adjusted for age; BMI, duration and type of dialysis.
p<0.05, statistically significant.
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In this study, we also found that serum GA levels were 
significantly influenced by serum albumin. However, there 
have been conflicting reports regarding the relationship be-
tween serum albumin and GA. Koga, et al.27 reported that 
serum GA levels could be affected by various conditions 
with abnormal metabolism of albumin. Under certain con-
ditions with shortened albumin metabolism, such as hyper-
thyroidism, nephrotic syndrome, PD or administered gluco-
corticoid treatments, serum GA levels are apparently low, 
whereas it may be high when albumin metabolism is pro-
longed, as in liver cirrhosis. However, Inaba, et al.16 could 
not confirm this finding. In their study with HD patients, se-
rum albumin did not act as a significant determinant of GA. 
We considered that the conflicting results might come from 
different ranges of baseline serum albumin concentrations. 
In our study, serum albumin level widely ranged from 2.3 
to 4.9 g/dL and a substantial portion of PD patients showed 
significant hypoalbuminemia of less than 3.0 g/dL. Particu-
larly, most of these patients revealed lower levels of GA. 
However, further large-scale studies with heterogeneous di-
alysis patients are needed to substantiate our observation. 
Next, a slight difference in the correlations between GA 
levels and mean AG values according to each SMBG time 
point were found. Serum GA levels were more strongly 
correlated with postprandial glucose level, compared to 
fasting glucose level. In multiple regression models, only 
postprandial glucose level was a significant contributing 
factor for serum GA (p=0.02). Considering that postprandi-
al hyperglycemia is still present in 40% of patients who had 
achieved their glycemic target and that the loss of postpran-
dial glycemic control is the first step for the deterioration of 
glucose homeostasis in type 2 diabetes,28 our finding is not 
surprising and emphasizes the importance of GA monitor-
ing.29 Furthermore, data from large studies underlined the 
independent role of postprandial hyperglycemia in the in-
creasing risk of mortality.30-32 Even when HbA1c and fasting 
glucose levels are within normal ranges, postprandial hy-
perglycemia is associated with a two-fold increase in the 
risk of cardiovascular mortality.33 Recently, postprandial 
hyperglycemia has been linked to microvascular complica-
tions as well. In Shiraiwa, et al.’s34 study with Japanese type 
2 diabetic patients, postprandial hyperglycemia was a strong 
predictor of the progression of diabetic retinopathy. There-
fore, GA values, affected by postprandial glucose level, 
may be a useful indicator for detecting and preventing dia-
betic complications.
However, although GA provides a quantitative measure 
explanatory power was observed between AG and GA 
(r=0.70, p<0.001) compared to HbA1c (r=0.54, p<0.001). 
Also, we evaluated how to calculate eAG level from GA 
and developed an estimating equation with a regression line 
of eAG=4.71×GA%+73.35. Using this mathematical equa-
tion, a serum GA level of 18-19% could be matched to an 
eAG level of 155-160 mg/dL, and each change of 10 mg/
dL in blood glucose could give rise to a 2% increase in GA 
level. Conceptually, converting the GA results into an equiv-
alent “average glucose” level might help our understanding 
with the interpretation of GA. 
To date, serum GA has been suggested as a more reliable 
and sensitive marker for gestational diabetes, hemolytic 
anemia and other diseases that shorten the lifespan of eryth-
rocytes,24 while a number of studies have investigated the 
effectiveness of GA and reviewed its clinical relevance.25 
One of them, Inaba, et al.16 confirmed its superiority in 
1366 Japanese hemodialysis patients. In that study, HbA1c 
levels were significantly higher in patients without erythro-
poietin use, supporting that HbA1c levels are influenced by 
renal anemia. Peacock, et al.12 also evaluated the accuracy 
of GA in US diabetic hemodialysis patients and empha-
sized the importance of GA measurement for long-term 
glycemic control. However, most previous studies to date 
have included only hemodialysis patients; therefore, this 
conclusion might not be applicable to patients with in-
creased albumin loss, as seen in nephrotic syndrome or PD, 
because albumin leaks into the peritoneal dialysis solu-
tion.15 To our knowledge, this is the first study where a gen-
eralized estimating equation method was evaluated in all 
ESRD patients including PD patients. 
In our study, the mean GA/HbA1c value was 2.8±0.9 in 
all participants and 3.1±0.8 in the diabetic group. This re-
sult is in good agreement with previous studies and could 
give additional support to the usually recognized simple 
equation of GA=HbA1c×3. However, this simple equation 
might be more suitable for diabetic ESRD patients only, be-
cause the GA, HbA1c and GA/HbA1c ratio of non-diabetic 
ESRD patients was 10.9, 5.8 and 1.9 in our study. Namely, 
the simple GA/HbA1c ratio of 3.0 could not be applied to 
non-diabetic ESRD patients. Nevertheless, monitoring of 
the plasma glucose is also important in non-diabetic pa-
tients, since many patients develop diabetes after initiation 
of dialysis, particularly with PD.26 Therefore, compared to 
GA, HbA1c and GA/HbA1c ratios, serum blood glucose lev-
el could be a more useful tool for screening for the develop-
ment of diabetes in non-diabetic ESRD patients.
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